AO
AORT.US Artivion Inc
- Market cap
- USD 932M
- P/E
- -
- P/B
- 2.09x
- ROE
- -6.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AORT.US undervalued?
Graham numberThe Graham number of Artivion Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Artivion Inc fundamental analysis
No fundamental analysis for Artivion Inc yet.
Artivion Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Artivion Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides…
Full company profileArtivion Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Artivion Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 180M | 190M | 263M | 276M | 253M | 299M | 314M | 354M | 389M | 441M | 488M |
| Gross Profit | 119M | 129M | 173M | 183M | 168M | 198M | 203M | 229M | 249M | 270M | 304M |
| Operating Income | 21.8M | 7.97M | 9.31M | 17.0M | 2.44M | 8.12M | 6.20M | 5.74M | 38.9M | 26.7M | 2.76M |
| EBITDA | 25.3M | 18.2M | 30.2M | 34.8M | 27.4M | 26.0M | 25.7M | 26.8M | 51.0M | 63.8M | 32.4M |
| Net Income | 10.8M | 3.70M | -3.81M | 1.72M | -16.7M | -14.8M | -19.2M | -30.7M | -13.4M | 9.77M | -26.7M |
| EPS | 0.33 | 0.11 | -0.10 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 | -0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 316M | 592M | 571M | 606M | 789M | 793M | 763M | 792M | 789M | 885M | 1.04B |
| Total Liabilities | 107M | 313M | 296M | 320M | 461M | 492M | 478M | 511M | 513M | 437M | 596M |
| Shareholders' Equity | 209M | 279M | 275M | 286M | 329M | 301M | 284M | 282M | 276M | 448M | 446M |
| Cash & Short-term Investments | 57.3M | 40.8M | 41.5M | 33.8M | 61.4M | 55.0M | 39.4M | 58.9M | 53.5M | 64.9M | 48.4M |
| Total Debt | 71.6M | 226M | 224M | 245M | 317M | 362M | 357M | 358M | 362M | 292M | 407M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.7M | 10.8M | 9.88M | 15.8M | 12.4M | -2.59M | -5.15M | 18.8M | 22.2M | 39.9M | -6.22M |
| Capital Expenditure | 7.42M | 7.04M | 5.79M | 8.07M | 7.33M | 13.1M | 10.7M | 7.43M | 11.2M | 39.0M | 42.4M |
| Free Cash Flow | 12.3M | 3.76M | 4.10M | 7.76M | 5.04M | -15.7M | -15.9M | 11.4M | 11.0M | 839K | -48.6M |
| Ratios | |||||||||||
| ROE | 5.2% | 1.3% | -1.4% | 0.6% | -5.1% | -4.9% | -6.7% | -10.9% | -4.8% | 2.2% | -6.0% |
| ROA | 3.4% | 0.6% | -0.7% | 0.3% | -2.1% | -1.9% | -2.5% | -3.9% | -1.7% | 1.1% | -2.6% |
| Net Profit Margin | 6.0% | 2.0% | -1.4% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% | -5.5% |
| Debt to Equity | 0.34x | 0.81x | 0.81x | 0.86x | 0.97x | 1.20x | 1.25x | 1.27x | 1.31x | 0.65x | 0.91x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Artivion Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 9, 2015
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 3.76M | 0.10 | - |
| 2020 | USD 2.43M | 0.06 | - |
| 2019 | USD 4.76M | 0.13 | 276.6% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Dec 28, 2000.
Who owns Artivion Inc
- Insiders 4.45%
- Institutions 95.55%
- Public & others 0.00%
- Shares outstanding 48.8M
- Free float 46.4M
Top funds holding AORT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.93M | 6.00% | -0.31% | Oct 2026 |
| Nomura Small Cap Core I | 1.90M | 3.89% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.46M | 3.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.15M | 2.35% | 0.00% | Oct 2026 |
| Fidelity Small Cap Value Fund | 947K | 1.94% | +55.12% | Aug 2026 |
| Conestoga Small Cap Investors | 756K | 1.55% | -19.73% | Sep 2026 |
| Fidelity Small Cap Index | 500K | 1.03% | +0.27% | Aug 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 443K | 0.91% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 441K | 0.90% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 429K | 0.88% | -0.38% | Oct 2026 |
| Alger Small Cap Focus I | 337K | 0.69% | 0.00% | Aug 2026 |
| First Eagle Small Cap Opportunity I | 331K | 0.68% | 0.00% | Sep 2026 |
| AMG GW&K Small Cap Core N | 296K | 0.61% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 276K | 0.57% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 266K | 0.55% | +1.20% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 260K | 0.53% | +0.23% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 256K | 0.53% | 0.00% | Sep 2026 |
| Royce Small-Cap Opportunity Invmt | 254K | 0.52% | +28.01% | Sep 2026 |
| Fidelity Advisor Small Cap I | 250K | 0.51% | 0.00% | Aug 2026 |
| Alger Weatherbie Specialized Growth A | 243K | 0.50% | -5.15% | Aug 2026 |
Top institutions holding AORT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 6.67M | 13.68% | +3.08% | Jun 2026 |
| Delaware Management Holdings Inc | 3.18M | 6.53% | +29.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.56M | 5.24% | +12.72% | Jun 2026 |
| Juniper Investment Co, LLC | 2.02M | 4.14% | +69.86% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.00M | 4.11% | +2.70% | Jun 2026 |
| FMR Inc | 1.96M | 4.02% | -24.00% | Jun 2026 |
| State Street Corp | 1.86M | 3.81% | +10.45% | Jun 2026 |
| Ophir Asset Management Pty Ltd | 1.80M | 3.69% | +89.31% | Jun 2026 |
| Perceptive Advisors LLC | 1.74M | 3.56% | +6.11% | Jun 2026 |
| Conestoga Capital Advisors, LLC | 1.62M | 3.33% | +38.14% | Jun 2026 |
| Wellington Management Company LLP | 1.26M | 2.58% | +8.96% | Jun 2026 |
| Geode Capital Management, LLC | 1.11M | 2.28% | -1.61% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 1.02M | 2.10% | +54.94% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.02M | 2.09% | +7.68% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 988K | 2.03% | -4.74% | Jun 2026 |
| Citadel Advisors Llc | 828K | 1.70% | +1,067.78% | Jun 2026 |
| GW&K Investment Management, LLC | 794K | 1.63% | +7.55% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 693K | 1.42% | +122.45% | Jun 2026 |
| Royce & Associates, LP | 639K | 1.31% | +50.32% | Jun 2026 |
| YARGER WEALTH STRATEGIES, LLC | 634K | 1.30% | 0.00% | Jun 2026 |
Artivion Inc company profile
- Company name
- Artivion Inc
- Ticker
- AORT.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 1993
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,800
- Fiscal year end
- December
- Address
- 1655 Roberts Boulevard NW, Kennesaw, GA, United States, 30144
- Phone
- 770 419 3355
- Website
- artivion.com
About Artivion Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Artivion Inc management
10- Mr. James Patrick MackinChairman, President & CEO · born 1967
- Mr. Lance A. Berry CPAEVP, COO, CFO & Treasurer · born 1972
- Ms. Jean F. Holloway Esq.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary · born 1957
- Mr. John E. DavisSenior VP & Chief Commercial Officer · born 1965
- Ms. Amy D. Horton CPAVP & Chief Accounting Officer · born 1970
- Mr. Matthew A. GetzVP of Human Resources & Chief Human Resources Officer · born 1969
- Mr. Jason D. AsperSenior VP and Chief Strategy & Digital Officer · born 1976
- Mr. Andrew M. GreenSenior Vice President of Regulatory & Quality · born 1969
- Dr. Simona Zannetti M.D.Senior Vice President of Clinical Research & Chief Medical Officer
- Dr. Robert C. Thomson Ph.D.Vice President of Research & Development · born 1971